Knottin-Drug Conjugates Targeting Integrins for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional cancer treatment chemotherapies often cause severe side effects due to non-selective targeting of cancer and healthy cells, and are limited in their ability to diffuse into tumors, particularly in brain and pancreatic cancers, leading to reduced therapeutic efficacy.
Innovation Solution
Development of knottin-drug conjugates, which consist of a knottin peptide with an engineered loop that binds to cancer cell surfaces and a nucleoside drug conjugated through a linker, allowing for targeted delivery of the drug to cancer cells while minimizing impact on healthy tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapy is used, then cancer cells can be treated, but severe side effects occur due to non-selective targeting of healthy cells
Solution Approach 1:
The patent uses knottin peptides as intermediary carriers that selectively bind to integrin receptors on cancer cell surfaces. These knottin-drug conjugates serve as mediators between the drug payload and target cells, enabling selective delivery to cancer cells while sparing healthy cells, thus resolving the contradiction between therapeutic efficacy and side effects
Solution Approach 2:
The invention modifies the local properties of the drug delivery system by creating knottin peptides with specific loop regions engineered to recognize and bind to integrin receptors. This localized recognition capability ensures that the therapeutic effect is concentrated at the cancer cell surface while minimizing interaction with healthy tissues
2Productivity
If small molecule chemotherapeutics are used, then treatment can be administered, but diffusion into tumors is limited reducing therapeutic value
Solution Approach 1:
The patent creates composite structures by conjugating drug molecules to knottin peptides, forming knottin-drug conjugates. This composite approach combines the targeting capability of knottin peptides with the therapeutic activity of the drug payload, enabling active targeting to cancer cells and improving drug delivery efficiency and therapeutic value
3Object-affected harmful factors
If antibody-drug conjugates are used, then selective delivery to tumor cells is achieved, but the size and complexity increase
Solution Approach 1:
The patent extracts and utilizes only the essential targeting domain (knottin peptide with integrin-binding loop) separate from the full antibody structure. This extracted approach maintains the selective targeting function while dramatically reducing molecular size and complexity compared to full antibody-drug conjugates
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The knottin-drug conjugates demonstrate potent inhibition of various cancer cell lines with low-nanomolar affinity and specific internalization via integrin-mediated processes, releasing the drug intracellularly to effectively reduce cancer cell proliferation without premature drug release, thus enhancing therapeutic efficacy and reducing side effects.
Implementation Method 1
specific internalization via integrin-mediated processes
Implementation Method 2
specific internalization via integrin-mediated processes, releasing the drug intracellularly
Data Source
AI summary
Provided are knottin-drug conjugates. The conjugates include a knottin peptide that includes an engineered loop that binds to a target on a cancer cell surface, and a drug (e.g., a nucleoside drug) conjugated to the knottin peptide through a linker. Also provided are pharmaceutical compositions and kits that include the knottin-drug conjugates, as well as methods of using the knottin-drug conjugates, e.g., for therapeutic purposes.